CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 451 enrolled
Drug / intervention
Remdesivirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04847622
NCT04847622N/ACompleted

A Multi-centre, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.

NEAT ID Foundation·observational·Posted Apr 19, 2021·Updated Nov 29, 2024

In Brief

An observational study evaluating Remdesivir for Covid19. Completed, enrolled 451 participants across 12 sites in 5 countries.

Detailed Summary

This is a multi-centre, multi-country retrospective cohort study. At least 450COVID-19 cases from up to 20 participating study sites who meet all eligibility criteria will be included in the analysis. Deidentified data will be extracted from electronic medical record (EMR) databases, clinical registries, case series or additional sources from participating sites and countries, and then entered into a structured e-CRF system. addition, each site/country will be surveyed to determine the local standard of care therapy for COVID-19 infection and to determine if standard protocols were/are in place for the use of Remdesivir and if/how the protocols changed over time.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesFrance, Israel, Netherlands, Spain, United Kingdom
CollaboratorsGilead Sciences

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 19, 2021
Enrollment StartFeb 12, 2021
Primary CompletionApr 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.2 years ago

Interventions

Remdesivirdrug

treated with Remdesivir